Orexigen Therapeutic shares had a trading volume of 304K by the end of trading on Tuesday. Shares saw a steep increase in trading volume of 105.47% over the normal average daily volume.
Investors are more bullish recently as inferred by the fall in short interest. The company recorded a fall in short interest of -6.39% as of October 13, 2017 from the last reporting period. Short shares decreased from 1,368,021 to 1,280,635 over that timeframe. With short interest at 1,280,635 and short average daily volume at 452,096, days to cover is 3.0 and the percentage of shorted shares is 0.08% as of October 13.
Here are a few substantial investment firms who have updated their positions. As of the end of the quarter Simplex Trading, LLC had bought 8,011 shares growing its position 86.2%. The value of the investment in OREX went from $26,000 to $36,000 increasing 38.5% since the last quarter. As of quarter end Citadel Advisors LLC had disposed of a total of 8,620 shares trimming its stake by 41.2%. The value of the investment in (OREX) decreased from $61,000 to $26,000 a change of 57.4% for the reporting period.
Wells Fargo & Company/mn reduced its holdings by selling 44,799 shares a decrease of 98.2% in the quarter. Wells Fargo & Company/mn currently owns 839 shares worth $2,000. The value of the position overall is down by 98.5%. Citigroup Inc bolstered its ownership by buying 5,600 shares an increase of 1,866.7%. Citigroup Inc now holds 5,900 shares with a value of $13,000. The total value of its holdings increased 1,200.0%.
The company is down since yesterday’s close of 1.71. The P/E ratio is currently N/A and the market cap is 25.54M. As of the latest earnings report the EPS was $-9.70 with 15.60M shares outstanding.
Orexigen Therapeutics, Inc., launched on September 12, 2002, is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Business’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition..